COVID-19 Survivors Are Still in Need of Neuropsychiatric Support Two Years after Infection
- PMID: 37508966
- PMCID: PMC10377179
- DOI: 10.3390/brainsci13071034
COVID-19 Survivors Are Still in Need of Neuropsychiatric Support Two Years after Infection
Abstract
COVID-19 survivors have been reported to be at risk of long-term neuropsychiatric sequalae; however, prospective evidence in this regard is lacking. We prospectively assessed the occurrence of mental-health-domain-related symptoms over a 24-month period following COVID-19 onset in a cohort of 230 patients. Of them, 36.1% were still presenting with at least one symptom 24 months later. Across the study period, a significant reduction in overall symptoms from the onset was observed (p < 0.001); however, symptom prevalence was unchanged between the 12- and 24-month follow-ups across most symptomatic domains. At the 24-month follow-up, mental-health-domain-related symptoms only were higher than at the onset and were the most frequently reported symptoms. Dyspnea at the onset predicted both symptoms of psychiatric disorders (OR = 3.26, 95% CI = 1.22-8.70, and p = 0.019) and a lack of concentration and focus (OR = 3.17, 95% CI = 1.40-7.16, and p = 0.005) 24 months post-infection, with the number of comorbidities at the onset also predicting the occurrence of a lack of concentration and focus (OR = 1.52, 95% CI = 1.12-2.08, and p = 0.008). The findings of this study may have important public health implications, as they underlie the fact that COVID-19 survivors are still in need of neuropsychiatric support two years after infection.
Keywords: anxiety; cognition; depression; insomnia; long COVID; post-COVID syndrome.
Conflict of interest statement
M.C. has been a consultant/advisor to GW Pharma Limited, GW Pharma Italy SRL, and F. Hoffmann-La Roche Limited outside of this work. M.P. reports receiving grants and personal fees from Pfizer, MSD, Menarini, and Dia Sorin outside of this work. C.T. has received grants in the last two years from Correvio, Biotest, Biomerieux, Gilead, Angelini, MSD, Pfizer, Thermofisher, Zambon, Shionogi, Avir Pharma, and Hikma outside of this work. All of the other authors declare no conflict of interest.
Similar articles
-
Mental health symptoms one year after acute COVID-19 infection: Prevalence and risk factors.Rev Psiquiatr Salud Ment. 2023 Jan-Mar;16:38-46. doi: 10.1016/j.rpsm.2022.05.008. Epub 2022 Jun 17. Rev Psiquiatr Salud Ment. 2023. PMID: 35755492 Free PMC article.
-
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.Lancet Respir Med. 2022 Sep;10(9):863-876. doi: 10.1016/S2213-2600(22)00126-6. Epub 2022 May 11. Lancet Respir Med. 2022. PMID: 35568052 Free PMC article.
-
COVID-19-induced neuropsychiatric symptoms can persist long after acute infection: a 2-year prospective study of biobehavioral risk factors and psychometric outcomes.Ir J Psychol Med. 2024 Feb 14:1-8. doi: 10.1017/ipm.2023.53. Online ahead of print. Ir J Psychol Med. 2024. PMID: 38351842
-
New‑onset neuropsychiatric sequelae and 'long‑COVID' syndrome (Review).Exp Ther Med. 2022 Oct 4;24(5):705. doi: 10.3892/etm.2022.11641. eCollection 2022 Nov. Exp Ther Med. 2022. PMID: 36324612 Free PMC article. Review.
-
A systematic review and meta-analysis on prevalence of and risk factors associated with depression, anxiety and insomnia in infectious diseases, including COVID-19: a call to action.Mol Psychiatry. 2022 Aug;27(8):3214-3222. doi: 10.1038/s41380-022-01638-z. Epub 2022 Jun 6. Mol Psychiatry. 2022. PMID: 35668158 Free PMC article.
Cited by
-
Neurological and Psychiatric Disorders in the COVID-19 Era.Brain Sci. 2024 Apr 2;14(4):355. doi: 10.3390/brainsci14040355. Brain Sci. 2024. PMID: 38672007 Free PMC article.
-
Lessons learnt while designing and conducting a longitudinal study from the first Italian COVID-19 pandemic wave up to 3 years.Health Res Policy Syst. 2023 Oct 31;21(1):111. doi: 10.1186/s12961-023-01055-w. Health Res Policy Syst. 2023. PMID: 37907957 Free PMC article.
References
-
- Colizzi M., Peghin M., De Martino M., Bontempo G., Gerussi V., Palese A., Isola M., Tascini C., Balestrieri M. Mental health symptoms one year after acute COVID-19 infection: Prevalence and risk factors. Rev. Psiquiatr. Salud Ment. 2023;16:38–46. doi: 10.1016/j.rpsm.2022.05.008. - DOI - PMC - PubMed
-
- Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021;22:e102–e107. doi: 10.1016/S1473-3099(21)00703-9. - DOI - PMC - PubMed
-
- Badenoch J.B., Rengasamy E.R., Watson C., Jansen K., Chakraborty S., Sundaram R.D., Hafeez D., Burchill E., Saini A., Thomas L., et al. Persistent neuropsychiatric symptoms after COVID-19: A systematic review and meta-analysis. Brain Commun. 2022;4:fcab297. doi: 10.1093/braincomms/fcab297. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources